Business Wire

VERISILICON

21.3.2024 01:01:30 CET | Business Wire | Press release

Share
StarFive’s RISC-V Based JH-7110 Intelligent Vision Processing Platform Adopted VeriSilicon’s Display Processor IP

VeriSilicon (688521.SH) today announced the successful integration of its Display Processor IP DC8200 into StarFive’s JH-7110 RISC-V mass production SoC. With high performance, low power consumption and high security features, this collaboration delivers a complete intelligent vision processing platform solution tailored for diverse applications including cloud computing, industrial control, Network Attached Storage (NAS), tablets, and Human-Machine Interface (HMI).

VeriSilicon’s DC8200 IP supports advanced image quality enhancements, enabling user premium visual experiences. It can be configured to provide optimal solutions for target applications. By integrating VeriSilicon’s proprietary compression technology, DC8200 significantly reduces DDR bandwidth, thereby enhancing overall efficiency. Moreover, DC8200 supports dual operating systems and collaborates with the RISC-V CPU to meet diverse product requirements.

Additionally, DC8200 can form robust subsystems through seamless integration with VeriSilicon’s video/image processing IPs, delivering immersive experience to end users with crisp edge, fine detail enhancement, and rich color.

Thomas Xu, CEO of StarFive, said, “Our RISC-V based JH-7110 SoC performs a variety of complex video image processing and intelligent visual computing tasks, meeting the diverse real-time visual processing needs at the edge. VeriSilicon’s display processor IP offers high visual quality with low power consumption. We are committed to advancing innovation based on RISC-V technology. With companion pixel processing IP available through our IP partners, RISC-V based products can be brought to market at an accelerated pace.”

“Starfive’s JH-7110 is a leading RISC-V based intelligent vision processor equipped with advanced smart display capabilities. In the smart display domain, there exists a strong market demand for sophisticated image quality enhancement technologies,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “The Display Processor IP, as part of our extensive Glass-to-Glass (from camera-in to display-out) intelligent pixel processing IP portfolio, is engineered to deliver superior image quality while ensuring low power consumption. The integration of our DC8200 with JH-7110 is instrumental in driving the performance of numerous screens within the RISC-V ecosystem.”

About StarFive

Founded in 2018, StarFive is a Chinese local high-tech company with independent intellectual properties. As the leader of the RISC-V software and hardware ecosystem in China, StarFive provides world-leading products and solutions on RISC-V covering IP, SoC, development boards, etc.

StarFive has independently developed RISC-V CPU IPs and NoC IPs, of which Dubhe-90 is the max performance commercial RISC-V CPU IP in China, and StarLink-700 is the first mesh coherent interconnect fabric IP in China. Based on these core IPs, StarFive can also provide customers with RISC-V subsystem IP solutions for multi-core, big.little core, and manycore. These products can be applied in high-performance and energy-efficient scenarios, including industrial control, desktop computing, mobile, network communication, machine learning, artificial intelligence, and data centers. Meanwhile, StarFive has also delivered JH-7110 SoC, the world’s first high-performance RISC-V multimedia processor for mass-production. For more information, please visit https://www.starfivetech.com

About VeriSilicon

VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: http://www.verisilicon.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240319671767/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye